Literature DB >> 3308691

A reason for the cytolytic inefficiency of murine serum.

F Sassi1, F Hugo, M Muhly, A Khaled, S Bhakdi.   

Abstract

Murine serum exhibits very poor haemolytic and bactericidal activity. We report that this is due, at least in part, to the presence of a potent, naturally occurring plasma inhibitor of the terminal complement sequence. The inhibitor is a heat-stable euglobulin. It is highly effective in suppressing haemolysis following complement activation on target erythrocytes with heterologous serum. It also inhibits C3-independent reactive haemolysis of guinea-pig erythrocytes with human C5b-9. Current evidence indicates that the inhibitory factor acts at the C5b-7 stage by preventing binding of the terminal complement complex to cells undergoing complement attack. In this respect, the inhibitor differs from the previously recognized regulators of the terminal complement sequence including plasma S-protein. The inhibitor does not protect C5b-7-laden cells from the action of C8 and C9, and also does not suppress formation of haemolytically inactive SC5b-9 in the fluid phase. The action of murine inhibitory factor is not confined to the red cell, and its presence can totally abolish the bactericidal activity of human serum on a sensitive, rough E. coli K12 strain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308691      PMCID: PMC1453709     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  9 in total

1.  Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement.

Authors:  F Hugo; S Krämer; S Bhakdi
Journal:  J Immunol Methods       Date:  1987-05-20       Impact factor: 2.303

2.  Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay.

Authors:  B McLeod; P Baker; H Gewurz
Journal:  Immunology       Date:  1974-06       Impact factor: 7.397

3.  Does complement kill E. coli by producing transmural pores?

Authors:  J Born; S Bhakdi
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

Review 4.  Membrane damage by complement.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Biochim Biophys Acta       Date:  1983-08-11

5.  Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components.

Authors:  E R Podack; H J Müller-Eberhard
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

6.  Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.

Authors:  B Dahlbäck; E R Podack
Journal:  Biochemistry       Date:  1985-04-23       Impact factor: 3.162

7.  Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action.

Authors:  B McLeod; P Baker; H Gewurz
Journal:  Immunology       Date:  1975-01       Impact factor: 7.397

8.  A natural auto-inhibitory factor of the terminal complement pathway in serum of Ctenodactylus gondi.

Authors:  F Sassi; F Hugo; M Muhly; A Khaled; M S Ben Rachid; S Bhakdi
Journal:  Mol Immunol       Date:  1987-05       Impact factor: 4.407

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7.

Authors:  R A Thompson; P J Lachmann
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

  9 in total
  2 in total

1.  Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo.

Authors:  B Ziegler; S Lucke; E Köhler; B Hehmke; M Schlosser; S Witt; W Besch; M Ziegler
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

2.  Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection.

Authors:  Michael E Woodman; Anne E Cooley; Jennifer C Miller; John J Lazarus; Kathryn Tucker; Tomasz Bykowski; Marina Botto; Jens Hellwage; R Mark Wooten; Brian Stevenson
Journal:  Infect Immun       Date:  2007-04-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.